Clinical trials: ALK+ Non-Small-Cell Lung Carcinoma
Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative
Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer
This trial studies the use of genetics and shared decision making in improving care for patients with stage IVA-C non-small cell lung cancer.
- Conditions
- Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative, Health Care Provider
- Trial name
- NCT03944265
- Testing
- Counseling, Questionnaire Administration, Medical Chart Review
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Alk-positive Non-Small Cell Lung Cancer, ALK-inhibitor Treated
ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study
The Goal of this observational study is to develop an AI-driven pathologic image analysis-based classifier that can identify patients unlikely to significantly benefit from the currently utilized first-line ALK inhibitors…
- Trial name
- ALKDigPath (NCT06846736)
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Sheba Medical Center
ALK-positive Advanced NSCLC, ALK-positive Non-small Cell Lung Cancer (NSCLC)
Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study
According to the Global Cancer Statistics 2022 report, lung cancer is the most common type of cancer (12.4% of the total) and the leading cause of cancer deaths (18.7% of total cancer deaths).
- Conditions
- ALK-positive Advanced NSCLC, ALK-positive Non-small Cell Lung Cancer (NSCLC), MPR, Neoadjuvant Therapy
- Trial name
- NCT06785584
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Medical University Union Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation
- Trial name
- PIKACHU (NCT04322890)
- Testing
- Osimertinib, Alectinib 150 MG, Crizotinib 250 MG
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Hunan Province Tumor Hospital
NSCLC, Stage III, ALK-rearrangement
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
BOUNCE is an international multicentre randomised phase II trial. The trial treatment consists of brigatinib 180 mg once daily p.o., with seven day lead-in at 90 mg once daily, for 3 years or until progression of disease.
- Trial name
- BOUNCE (NCT05718297)
- Testing
- Brigatinib, Durvalumab
- Where
- 20 sites in France, Italy and 3 more
- Sponsor
- ETOP IBCSG Partners Foundation
NSCLC, Crizotinib
Descriptive Observational Study ALK-2016-CPHG
Descriptive Observational Study. Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer (NSCLC) Treated With Crizotinib Within General Hospitals
- Conditions
- NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement
- Trial name
- ALK2016CPHG (NCT03718117)
- Where
- 26 sites in France
- Volunteers
- 73 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, ALK-positive
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of SAF-189s versus crizotinib treatment in participants with treatment-naive ALK-positive advanced NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, ALK-positive, SAF-189s
- Trial name
- NCT06569420
- Testing
- Drug: Foritinib Succinate, Drug: Crizotinib
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung…
- Trial name
- NCT01970865
- Testing
- PF-06463922, Crizotinib
- Where
- 77 sites in United States, Australia and 12 more
- Volunteers
- 364 people
- Sponsor
- Pfizer
ALK Gene Mutation, NSCLC Stage IV
Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
The scope of GALILEO project (Genomic ALteratIons and cLonal EvOlution in ALK+ NSCLC) is to explore the feasibility of genomic longitudinal evaluation for ALK+ NSCLC patients in Italian routine practice and provide a detailed…
- Conditions
- ALK Gene Mutation, NSCLC Stage IV, ALK Sensitizing Mutation
- Trial name
- GALILEO (NCT06234579)
- Testing
- Biopsy (tissue or liquid)
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ALK-positive Non-small Cell Lung Cancer, Brain Metastases
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
This study was a retrospective observational study. The study included patients with non-small cell lung cancer with ALK-fusion brain metastases or meningeal metastases who received first-line and late-line treatment with the…
- Conditions
- ALK-positive Non-small Cell Lung Cancer, Brain Metastases, Meningeal Metastasis
- Trial name
- NCT06410040
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
ALK-positive Non-small Cell Lung Cancer
Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
The main purpose of the study is to evaluate safety and efficacy of Alkotinib capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib.While exploring the relationship between biomarkers…
- Trial name
- NCT04211922
- Testing
- Alkotinib Capsules
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non Small Cell Lung Cancer Metastatic, ALK Gene Mutation
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
This study aims to evaluate the activity and safety of the combination of platinum-pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression…
- Trial name
- ALK-PPL (NCT06378892)
- Testing
- Lorlatinib
- Where
- 9 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
ALK-positive Non-small Cell Lung Cancer, Real World Study
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
This study was a multicenter, prospective, non-interventional clinical study that included first-line and late-line patients with advanced non-small cell lung cancer with ALK fusions treated with the third generation ALK-TKI…
- Trial name
- NCT06361589
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
ALK-positive Non-small-cell Lung Cancer
Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
To evaluate the clinical real world outcomes of lorlatinib in second/later line setting anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to TKI sequence sequence treatment after failure of alectinib as a…
- Trial name
- NCT04979988
- Testing
- Lortlatinib
- Where
- 16 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Pfizer
Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
Fusion of anaplastic lymphoma kinase (ALK) is an important driving gene for NSCLC, with an incidence rate of 3-7%. In patients with advanced ALK mutation NSCLC, first-line use of ALK inhibitors significantly improves progression…
- Trial name
- NCT06282536
- Testing
- Iruplinalkib, surgery
- Volunteers
- 20 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
NSCLC, NSCLC Stage IV
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer
This is a prospective, non-randomized, single arm, single institution phase II trial to evaluate the safety and effectiveness of stereotactic ablative radiotherapy (SABR) in oncogene addicted and non-oncogene addicted synchronous…
- Conditions
- NSCLC, NSCLC Stage IV, Oligometastatic Disease, Non Small Cell Lung Cancer
- Trial name
- STARTNEWERA-OM (NCT06207292)
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Radiotherapy Oncology Centre "Santa Maria" Hospital
ALK Positive Non-small Cell Lung Cancer
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
This phase II study is aim to investigate the efficacy, resistance mechanism, safety profile of first-line lorlatinib in China advanced ALK+ non-small cell lung cancer (NSCLC).
- Trial name
- NCT06092086
- Testing
- Loratinib
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Guangdong Association of Clinical Trials
Radiotherapy Side Effect, Non-small Cell Lung Cancer
Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)
The goal of this clinical trial is to learn evaluate the safety and efficacy of the addition of radiation therapy to all tumour lesions, to first line medical treatment with alectinib in non-small cell lung cancer harbouring…
- Conditions
- Radiotherapy Side Effect, Non-small Cell Lung Cancer, ALK Gene Mutation
- Trial name
- A-SAB (NCT05724004)
- Testing
- SBRT/SRS/radiation therapy
- Where
- Sweden
- Volunteers
- 70 people
- Sponsor
- Karolinska University Hospital
Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer…
- Conditions
- Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT01700582
- Where
- 133 sites in France
- Volunteers
- 17,664 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
This single-arm, open-label, phase II clinical study aims to evaluate the progression-Free Survival (PFS) of the combination of Alectinib plus Bevacizumab in untreated and first and second-line chemotherapy failed subjects with…
- Trial name
- NCT03779191
- Testing
- Alectinib, Bevacizumab
- Where
- Mexico
- Volunteers
- 41 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico